PURPOSE: To evaluate the clinical outcomes and relationship between tumor size, lymph node status, and prognosis in a large cohort of patients with confirmed triple receptor-negative breast cancer (TNBC). PATIENTS AND METHODS: We reviewed 1,711 patients with TNBC diagnosed between 1980 and 2009. Patients were categorized by tumor size and nodal status. Kaplan-Meier product limit method was used to calculate overall survival (OS) and relapse-free survival (RFS). A Sidak adjustment was used for multiple group comparisons. Cox proportional hazards models were fit to determine the association of tumor size and nodal status with survival outcomes after adjustment for other patient and disease characteristics. RESULTS: Median age was 48 years (range, 21 to 87 years). At a median follow-up of 53 months (range, 0.7 to 317 months), there were 614 deaths and 747 recurrences. The 5-year OS was 80% for node-negative patients (N0), 65% for one to three positive lymph nodes (N1), 48% for four to nine positive lymph nodes (N2), and 44% for ≥ 10 positive lymph nodes (N3; P < .0001). The 5-year RFS rates were 67% for N0, 52% for N1, 36% for N2, and 33% for N3 (P < .0001). Pairwise comparison by nodal status showed that when comparing N0 with node-positive disease, there was a significant difference in OS and RFS (P < .001 all comparisons). However, when comparing N1 with N2 and N3 disease regardless of tumor size, there were no significant differences in OS or RFS. CONCLUSION: In patients with TNBC, once there is evidence of lymph node metastasis, the prognosis may not be affected by the number of positive lymph nodes.
PURPOSE: To evaluate the clinical outcomes and relationship between tumor size, lymph node status, and prognosis in a large cohort of patients with confirmed triple receptor-negative breast cancer (TNBC). PATIENTS AND METHODS: We reviewed 1,711 patients with TNBC diagnosed between 1980 and 2009. Patients were categorized by tumor size and nodal status. Kaplan-Meier product limit method was used to calculate overall survival (OS) and relapse-free survival (RFS). A Sidak adjustment was used for multiple group comparisons. Cox proportional hazards models were fit to determine the association of tumor size and nodal status with survival outcomes after adjustment for other patient and disease characteristics. RESULTS: Median age was 48 years (range, 21 to 87 years). At a median follow-up of 53 months (range, 0.7 to 317 months), there were 614 deaths and 747 recurrences. The 5-year OS was 80% for node-negative patients (N0), 65% for one to three positive lymph nodes (N1), 48% for four to nine positive lymph nodes (N2), and 44% for ≥ 10 positive lymph nodes (N3; P < .0001). The 5-year RFS rates were 67% for N0, 52% for N1, 36% for N2, and 33% for N3 (P < .0001). Pairwise comparison by nodal status showed that when comparing N0 with node-positive disease, there was a significant difference in OS and RFS (P < .001 all comparisons). However, when comparing N1 with N2 and N3 disease regardless of tumor size, there were no significant differences in OS or RFS. CONCLUSION: In patients with TNBC, once there is evidence of lymph node metastasis, the prognosis may not be affected by the number of positive lymph nodes.
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Socorro María Rodríguez-Pinilla; David Sarrió; Emiliano Honrado; David Hardisson; Francisco Calero; Javier Benitez; José Palacios Journal: Clin Cancer Res Date: 2006-03-01 Impact factor: 12.531
Authors: S Eva Singletary; Craig Allred; Pandora Ashley; Lawrence W Bassett; Donald Berry; Kirby I Bland; Patrick I Borgen; Gary M Clark; Stephen B Edge; Daniel F Hayes; Lorie L Hughes; Robert V P Hutter; Monica Morrow; David L Page; Abram Recht; Richard L Theriault; Ann Thor; Donald L Weaver; H Samuel Wieand; Frederick L Greene Journal: Surg Clin North Am Date: 2003-08 Impact factor: 2.741
Authors: Gregory Weitsman; Katherine Lawler; Muireann T Kelleher; James E Barrett; Paul R Barber; Eamon Shamil; Frederic Festy; Gargi Patel; Gilbert O Fruhwirth; Lufei Huang; Iain D C Tullis; Natalie Woodman; Enyinnaya Ofo; Simon M Ameer-Beg; Sheeba Irshad; John Condeelis; Cheryl E Gillett; Paul A Ellis; Borivoj Vojnovic; Anthony C C Coolen; Tony Ng Journal: Biochem Soc Trans Date: 2014-12 Impact factor: 5.407
Authors: Farrell C Adkins; Ana Maria Gonzalez-Angulo; Xiudong Lei; Leonel F Hernandez-Aya; Elizabeth A Mittendorf; Jennifer K Litton; Jamie Wagner; Kelly K Hunt; Wendy A Woodward; Funda Meric-Bernstam Journal: Ann Surg Oncol Date: 2011-09-27 Impact factor: 5.344
Authors: Neta S Zuckerman; Hongxiang Yu; Diana L Simons; Nupur Bhattacharya; Valeria Carcamo-Cavazos; Ning Yan; Frederick M Dirbas; Denise L Johnson; Erich J Schwartz; Peter P Lee Journal: Int J Cancer Date: 2012-11-26 Impact factor: 7.396
Authors: Ibrahim Turker; Ulku Y Arslan; Ozan Yazici; Ummugul Uyeturk; Berna Oksuzoglu; Burcin Budakoglu; Nuriye Özdemir; Ozlem U Sonmez; Kaan Helvaci; Onur Esbah; Oznur Bal; Ahmet S Ekinci; Nurullah Zengin Journal: Breast Care (Basel) Date: 2014-12 Impact factor: 2.860
Authors: Lianjin Jin; Meng Lim; Shuping Zhao; Yuri Sano; Brittany A Simone; Jason E Savage; Eric Wickstrom; Kevin Camphausen; Richard G Pestell; Nicole L Simone Journal: Breast Cancer Res Treat Date: 2014-05-27 Impact factor: 4.872
Authors: Zachary S Zumsteg; Monica Morrow; Brittany Arnold; Junting Zheng; Zhigang Zhang; Mark Robson; Tiffany Traina; Beryl McCormick; Simon Powell; Alice Y Ho Journal: Ann Surg Oncol Date: 2013-05-19 Impact factor: 5.344